Eli Lilly has achieved significant milestones in its development of orforglipron, an oral obesity pill, following the successful Phase III ATTAIN-2 trial. The trial results have not only demonstrated substantial weight loss benefits but also highlighted a key manufacturing advantage that could lead to a substantial market opportunity for the company. With a weight reduction of over 10% in patients with type II diabetes and overweight or obesity, Lilly now possesses compelling data to support a forthcoming FDA application.
The findings from the Phase III ATTAIN-2 study, unveiled recently, showcased the remarkable efficacy of orforglipron in promoting weight loss. Patients treated with a 36-mg dose of orforglipron for 72 weeks exhibited a significant weight reduction of 10.5%, equivalent to approximately 22.9 lbs, compared to a modest 2.2% (5.1 lbs) weight loss observed in the placebo group over the same period. Even when considering all patients, irrespective of adherence levels, orforglipron still led to a notable 9.6% decrease in weight at the 36 mg dosage compared to a 2.5% reduction in the placebo group.
The positive outcomes from the ATTAIN-2 trial have bolstered investor confidence, reflected in a 3% increase in Eli Lilly’s shares during pre-market trading following the trial’s publication. Building upon the data from both the ATTAIN-1 and ATTAIN-2 studies, Lilly is now poised to initiate the regulatory approval process for orforglipron, with plans to submit an application to the FDA later this year. Analysts from Truist Securities have acknowledged the encouraging findings from ATTAIN-2, emphasizing the potential market competitiveness of orforglipron, particularly citing its advantageous manufacturing profile that could pave the way for a substantial revenue opportunity, estimated at $14.7 billion in peak sales.
Beyond its weight loss benefits, orforglipron treatment also exhibited improvements in glucose control among diabetic patients. Noteworthy reductions in blood A1C levels were observed in patients receiving the highest dose of 36 mg, in contrast to minimal changes in the placebo group. Safety assessments from the ATTAIN-2 trial indicated that orforglipron’s profile aligns with the broader GLP-1 class, with no new safety signals identified. However, gastrointestinal side effects typical of GLP-1 therapies, including nausea, vomiting, constipation, and diarrhea, were reported, leading to treatment discontinuations in up to 10.9% of patients in the orforglipron arms.
Looking ahead, Lilly plans to present more detailed findings from the ATTAIN-2 trial at an upcoming medical conference, further solidifying the clinical profile of orforglipron. The recent positive data from ATTAIN-2 follows closely on the heels of results from the Phase III ATTAIN-1 study, which focused on patients with overweight or obesity but without diabetes. In the ATTAIN-1 trial, orforglipron demonstrated a notable 12.4% reduction in body weight at the same 36 mg dose level and duration, outperforming the placebo group by a significant margin. Despite these promising results, some investors and analysts have expressed reservations about orforglipron’s efficacy, particularly in comparison to injectable semaglutide, which exhibited higher weight loss rates in previous trials.
In conclusion, Eli Lilly’s progress with orforglipron marks a significant advancement in the field of oral obesity treatments, with the company poised to submit a regulatory application based on compelling Phase III data. The manufacturing advantage and substantial weight loss benefits observed in clinical trials position orforglipron as a potential game-changer in the obesity market, offering a promising therapeutic option for patients with type II diabetes and overweight or obesity. As Lilly continues to navigate the regulatory pathway, further insights from upcoming conferences and additional data disclosures will provide a comprehensive understanding of orforglipron’s clinical profile and market potential.
- Eli Lilly’s successful Phase III trials for orforglipron demonstrate significant weight loss benefits and a promising manufacturing advantage.
- Orforglipron has shown efficacy in reducing body weight and improving glucose control in patients with type II diabetes and overweight or obesity.
- Safety data from the trials indicate a favorable profile aligned with the broader GLP-1 class, with manageable gastrointestinal side effects.
- Lilly’s plans to share detailed trial findings at upcoming conferences reflect a commitment to transparency and continued scientific advancement.
Read more on biospace.com